总市值

Search documents
理邦仪器收盘下跌2.83%,滚动市盈率40.15倍,总市值75.76亿元
Sou Hu Cai Jing· 2025-08-14 10:18
Core Viewpoint - The company, Lifetech Scientific Corporation, is currently facing a decline in stock price and performance metrics, with a PE ratio lower than the industry average, indicating potential undervaluation in the medical device sector [1][2]. Company Summary - Lifetech Scientific Corporation's stock closed at 13.07 yuan, down 2.83%, with a rolling PE ratio of 40.15 times and a total market capitalization of 7.576 billion yuan [1]. - The company operates in the medical device sector, focusing on the research, production, sales, and service of medical electronic devices and in vitro diagnostic products [1]. - Key products include critical care monitoring solutions, bedside monitoring solutions, smart vital sign management solutions, various ECG and ultrasound systems, and molecular diagnostic products [1]. Financial Performance - For the first quarter of 2025, the company reported revenue of 420 million yuan, a year-on-year decrease of 5.25%, while net profit was 65.0882 million yuan, reflecting a year-on-year increase of 68.98% [1]. - The sales gross margin stood at 58.34% [1]. Industry Summary - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, positioning Lifetech Scientific Corporation at the 78th rank within the industry [1][2]. - The company is held by four institutions, all of which are funds, with a total holding of 55,200 shares valued at 0.01 million yuan [1].
中设股份收盘下跌2.48%,滚动市盈率2536.63倍,总市值19.00亿元
Sou Hu Cai Jing· 2025-08-14 10:00
Group 1 - The core viewpoint of the articles highlights the significant disparity between the price-to-earnings (PE) ratio of the company and the industry average, indicating potential overvaluation [1][2] - The company's current PE ratio is 2536.63, which is substantially higher than the industry average of 65.28 and the median of 39.48, ranking it 43rd in the industry [1][2] - As of July 31, 2025, the number of shareholders for the company has increased to 32,358, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - The main business of Jiangsu Zhongshe Group Co., Ltd. revolves around providing comprehensive engineering design consulting and general contracting services in four key areas: transportation, municipal, construction, and environment [1] - The latest financial performance for Q1 2025 shows a revenue of 37.16 million yuan, representing a year-on-year decline of 73.79%, with a net profit of 543,800 yuan, down 94.54% compared to the previous year, and a gross margin of 35.63% [1]
南京商旅收盘上涨1.94%,滚动市盈率113.86倍,总市值35.94亿元
Sou Hu Cai Jing· 2025-08-13 10:29
Core Viewpoint - Nanjing Commercial Travel's stock closed at 11.57 yuan, with a PE ratio of 113.86, significantly higher than the industry average of 47.22 [1][2] Company Summary - Nanjing Commercial Travel's main business includes commercial trade and tourism, with key products being textiles, machinery, chemicals, metals, non-metallic minerals, tourism services, and retail [1] - As of March 31, 2025, the company had 30,086 shareholders, a decrease of 906 from the previous period, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Financial Performance - In the first quarter of 2025, the company reported revenue of 191 million yuan, a year-on-year decrease of 7.98%, and a net profit of 3.51 million yuan, down 80.03% year-on-year, with a gross margin of 22.30% [1]
大博医疗收盘下跌1.34%,滚动市盈率64.30倍,总市值256.03亿元
Sou Hu Cai Jing· 2025-08-13 09:12
Core Viewpoint - Dabo Medical's stock closed at 61.84 yuan on August 13, with a PE ratio of 64.30, indicating a higher valuation compared to the industry average [1] Company Summary - Dabo Medical specializes in the production, research, and sales of high-value medical consumables, including a wide range of orthopedic and surgical products [1] - The latest quarterly report for Q1 2025 shows a revenue of 550 million yuan, a year-on-year increase of 28.80%, and a net profit of 103 million yuan, up 67.04%, with a gross margin of 69.64% [1] Industry Summary - The average PE ratio for the medical device industry is 57.48, with a median of 40.95, positioning Dabo Medical at the 90th rank within the industry [2] - The total market capitalization of Dabo Medical is 25.603 billion yuan, which is significantly higher than the industry average market cap of 12.064 billion yuan [2]
伟思医疗收盘上涨5.40%,滚动市盈率47.16倍,总市值53.50亿元
Sou Hu Cai Jing· 2025-08-12 11:21
Company Overview - Weisi Medical's stock closed at 55.86 yuan, up 5.40%, with a rolling PE ratio of 47.16, marking a new low in 340 days, and a total market capitalization of 5.35 billion yuan [1] - The company operates in the medical device sector, focusing on the research, production, and sales of medical devices, including magnetic stimulation, electrical stimulation, electrophysiology, consumables, and laser radiofrequency products [1] Financial Performance - For Q1 2025, Weisi Medical reported revenue of 95.91 million yuan, a year-on-year increase of 9.40%, and a net profit of 33.22 million yuan, reflecting a year-on-year growth of 52.71%, with a gross profit margin of 66.65% [1] Shareholder Information - As of March 31, 2025, Weisi Medical had 5,933 shareholders, an increase of 637 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 57.51, with a median of 41.25, placing Weisi Medical at the 83rd position in the industry ranking [1] - The industry average PE ratio is 57.51, while the median is 41.25, indicating that Weisi Medical's PE ratio is below the industry average [2]
安杰思收盘上涨4.03%,滚动市盈率23.31倍,总市值68.74亿元
Sou Hu Cai Jing· 2025-08-12 11:21
截至2025年半年报,共有10家机构持仓安杰思,其中其他5家、基金4家、券商1家,合计持股数1763.84 万股,持股市值11.43亿元。 杭州安杰思医学科技股份有限公司的主营业务是内镜微创诊疗器械的研发、生产与销售。公司的主要产 品是GI类、EMR/ESD类、ERCP诊疗系列、诊疗仪器设备。公司获得多项政府荣誉,主要包括"浙江省 出口名牌"称号,"临平区人民政府质量奖"等奖项。 8月12日,安杰思今日收盘84.89元,上涨4.03%,滚动市盈率PE(当前股价与前四季度每股收益总和的 比值)达到23.31倍,创311天以来新低,总市值68.74亿元。 从行业市盈率排名来看,公司所处的医疗器械行业市盈率平均57.51倍,行业中值41.25倍,安杰思排名 第48位。 最新一期业绩显示,2025年半年报,公司实现营业收入3.02亿元,同比14.56%;净利润1.26亿元,同比 1.26%,销售毛利率70.21%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13安杰思23.3123.432.8368.74亿行业平均 57.5153.344.97120.28亿行业中值41.2539.962.9558.75亿 ...
南微医学收盘上涨3.73%,滚动市盈率29.70倍,总市值180.03亿元
Sou Hu Cai Jing· 2025-08-12 10:58
Group 1 - The core viewpoint of the articles highlights that Nanwei Medical's stock price closed at 95.84 yuan, with a 3.73% increase, and a rolling PE ratio of 29.70, marking a new low in 391 days, with a total market capitalization of 18.003 billion yuan [1] - The average PE ratio for the medical device industry is 57.51, with a median of 41.25, placing Nanwei Medical at the 57th position in the industry ranking [1] - As of the 2025 semi-annual report, 25 institutions hold shares in Nanwei Medical, including 18 funds, 3 social security funds, 3 others, and 1 brokerage, with a total holding of 106.2244 million shares valued at 7.175 billion yuan [1] Group 2 - Nanwei Medical specializes in the research, manufacturing, and sales of minimally invasive medical devices, with key products including endoscopic diagnostic devices, microwave/radiofrequency ablation equipment and consumables, and disposable endoscopes [1] - The latest performance report for the first half of 2025 shows that the company achieved an operating income of 1.565 billion yuan, a year-on-year increase of 17.36%, and a net profit of 363 million yuan, also a year-on-year increase of 17.04%, with a gross profit margin of 64.89% [1] - The TTM PE ratio for Nanwei Medical is 29.70, while the static PE is 32.54, and the price-to-book ratio is 4.47 [2]
中曼石油收盘上涨2.45%,滚动市盈率11.62倍,总市值90.94亿元
Sou Hu Cai Jing· 2025-08-12 10:47
Company Overview - Zhongman Petroleum's closing price on August 12 was 19.67 yuan, reflecting a 2.45% increase, with a rolling PE ratio of 11.62 times and a total market capitalization of 9.094 billion yuan [1] - The company ranks 9th in the exploration and extraction industry, which has an average PE ratio of 30.06 times and a median of 39.60 times [1][2] - As of the first quarter of 2025, nine institutions held shares in Zhongman Petroleum, including eight funds and one brokerage, with a total holding of 6.6116 million shares valued at 133 million yuan [1] Business Operations - Zhongman Petroleum's main business includes exploration and development, oil service engineering, and petroleum equipment manufacturing [1] - Key products consist of equipment manufacturing, leasing and sales, drilling engineering services, and the sale of oil and its derivatives [1] Financial Performance - In the first quarter of 2025, Zhongman Petroleum reported operating revenue of 943 million yuan, a year-on-year increase of 16.90% [1] - The net profit for the same period was 230 million yuan, reflecting a year-on-year growth of 32.95%, with a sales gross margin of 45.97% [1]
美好医疗收盘上涨1.13%,滚动市盈率32.79倍,总市值117.24亿元
Sou Hu Cai Jing· 2025-08-12 10:05
Group 1 - The core viewpoint of the articles highlights the performance and valuation of Meihao Medical, which closed at 20.61 yuan with a PE ratio of 32.79, marking a 50-day low, and a total market capitalization of 11.724 billion yuan [1][2] - In terms of industry comparison, the average PE ratio for the medical device industry is 57.51, with a median of 41.25, positioning Meihao Medical at the 63rd rank within the industry [1][2] - The company has seen a net inflow of 41.2451 million yuan in principal funds on August 12, with a total inflow of 80.4884 million yuan over the past five days, indicating a positive trend in capital flow [1] Group 2 - Meihao Medical specializes in the design, development, manufacturing, and sales of precision components and products for medical devices, including home ventilator components and cochlear implant components [1] - The latest financial report for Q1 2025 shows that the company achieved a revenue of 296 million yuan, a year-on-year increase of 5.05%, while net profit was 51.875 million yuan, reflecting a year-on-year decrease of 10.62%, with a gross profit margin of 39.28% [1]
三博脑科收盘上涨4.82%,滚动市盈率112.80倍,总市值123.96亿元
Sou Hu Cai Jing· 2025-08-12 10:05
Group 1 - The core viewpoint of the news is that Sanbo Brain Science has seen a significant increase in its stock price, reaching 60.18 yuan, with a rise of 4.82%, while its rolling PE ratio has dropped to a new low of 112.80 times over the past 309 days, with a total market value of 12.396 billion yuan [1] - In terms of industry comparison, the average PE ratio for the medical services sector is 48.17 times, and the median is 63.54 times, placing Sanbo Brain Science at the 38th position within the industry [1] - The company experienced a net outflow of 3.9494 million yuan in principal funds on August 12, with a total outflow of 311.8002 million yuan over the past five days [1] Group 2 - Sanbo Brain Science Hospital Management Group Co., Ltd. primarily engages in clinical medical services, with its main products including medical services, pharmaceuticals, supply chain, and other businesses [1] - The latest performance report for the first quarter of 2025 indicates that the company achieved an operating income of 393 million yuan, representing a year-on-year increase of 16.78%, and a net profit of 38.3136 million yuan, up 14.56%, with a sales gross margin of 26.44% [1]